Skip to main content

Advertisement

SpringerLink
Log in

An Approach to Suspected Invasive Fungal Infection in Patients with Hematologic Malignancy and HCT Recipients with Persistent Neutropenic Fever Despite Mold-Active Prophylaxis

  • Current Management of Fungal Infections (S Jacobs, Section Editor)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review offers an approach to managing suspected invasive fungal infection (IFI) in a febrile neutropenic patient with hematologic malignancy or hematopoietic cell transplantation (HCT) while on mold-active prophylaxis. We take into consideration host characteristics, new diagnostic tools, and available therapeutics.

Recent Findings

Despite use of anti-Aspergillus prophylactic agents, invasive aspergillosis is the most commonly reported IFI breaking through common prophylactic agents including the newest azole, isavuconazole. While more fungal diagnostic modalities are available, how to best incorporate them in the work-up of IFI remains unclear, while sensitivity of any particular fungal biomarker or molecular test is low.

Summary

In a febrile neutropenic patient with hematologic malignancy or HCT and suspected IFI, consider particularly invasive aspergillosis, regardless of the mold-active prophylactic agent. Early diagnosis and intervention are especially important to a favorable outcome; treatment is directed based on the suspected IFI syndrome and suspected organism. Switching azoles, consideration of combination therapy, and reducing immunosuppression are proposed strategies for the management of breakthrough IFI, while surgical debridement remains crucial for Mucormycoses. More study is needed into the optimal antifungal approach in these clinical scenarios. Meanwhile, therapeutic drug monitoring and attention to drug-drug interactions are encouraged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Disease Society of America. Clin Infect Dis. 2011;52(4):e56–93.

    PubMed  Google Scholar 

  2. Ananda-Rajah MR, Slavin MA, Thursky KT. A case for antifungal stewardship. Curr Opin Infect Dis. 2012;25(1):107–15.

    PubMed  Google Scholar 

  3. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.

    PubMed  Google Scholar 

  4. Cornely OA, Maertens J, Winston DJ, Perfect JR, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.

    CAS  PubMed  Google Scholar 

  5. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo S, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.

    CAS  PubMed  Google Scholar 

  7. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled tiral of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.

    CAS  PubMed  Google Scholar 

  9. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.

    CAS  PubMed  Google Scholar 

  10. •• Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough invasive mold infections in the hematology patient: current concepts and future directions. Clin Infect Dis. 2018;67(10):1621–30 Approaches to and review of breakthrough invasive mold infections in hematology patients receiving mold-active antifungals.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.

    PubMed  Google Scholar 

  12. Pechlivanoglou P, Le HH, Daenen S, Snowden JA, Postma MJ. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. J Antimicrob Chemother. 2014;69:1–11 [cited 2019 Dec 22], Available from: http://www.clinicaltrials.gov.

    CAS  PubMed  Google Scholar 

  13. • Cornely OA, Hoenigl M, Lass-Flörl C, Chen SC -A., Kontoyiannis DP, Morrissey CO, et al. Defining breakthrough invasive fungal infection–position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. 2019;(June):716–729. Position paper that defines breakthrough invasive fungal infection.

  14. •• Patel HP, Perissinotti AJ, Patel TS, Bixby DL, Marshall VD, Marini BL. Incidence and risk factors for breakthrough invasive mold infections in acute myeloid leukemia patients receiving remission induction chemotherapy. Open Forum Infect Dis. 2019;6(5):ofz176 Epidemiologic study of breakthrough mold infections in AML patients.

    PubMed  PubMed Central  Google Scholar 

  15. Maschmeyer G, Patterson TF. Our 2014 approach to breakthrough invasive fungal infections. Mycoses. 2014;57(11):645–51.

    PubMed  Google Scholar 

  16. •• Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis. 2017;64(11):1619–21 Retrospective cohort study evaluating invasive mold infection in patients on azole prophylaxis at a single center.

    PubMed  Google Scholar 

  17. •• Kim SB, Cho SY, Lee DG, Choi JK, Lee HJ, Kim SH, et al. Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: a 5-year retrospective cohort study. Med Mycol. 2017;55(3):237–45 Retrospective cohort study of breakthrough invasive fungal infections of patients on voriconazole at a single center.

    CAS  PubMed  Google Scholar 

  18. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743–6.

    PubMed  Google Scholar 

  19. •• Lee HJ, Cho SY, Lee DG, Park C, Chun HS, Park YJ. Characteristics and risk factors for mortality of invasive non-Aspergillus mould infections in patients with haematologic diseases: a single-centre 7-year cohort study. h. 2019;(February):1–8 Cohort study reviewing non-Aspergillusmold infections in hematologic malignancy patients on mold-active antifungal prophylaxis.

  20. •• Fontana L, Perlin DS, Zhao Y, Noble BN, Lewis JS, Strasfeld L, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2019; EPub ahead of print. Restrospective review of hematologic malignancy and HCT patients on isavuconazole primary prophylaxis reporting incidence of breatkthrough IFI with comparison to voriconazole and posaconazole prophylaxis.

  21. • Barnes R, Rogers T, Maertens J. Defining standards of CARE for invasive fungal diseases in adult haematology patients: antifungal prophylaxis versus treatment. J Antimicrob Chemother. 2019;74:ii21–6 Discussion of pros and cons of antifungal prophylaxis versus pre-emptive treatment paired with IFI diagnostics in hematology patients.

    CAS  Google Scholar 

  22. Van De Peppel RJ, Dekkers OM, Von Dem Borne PA, De Boer MGJ. Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. Med Mycol. 2014;52(7):699–705.

    PubMed  Google Scholar 

  23. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006;42(11):1584–91.

    PubMed  Google Scholar 

  24. Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71(9):2634–41.

    PubMed  Google Scholar 

  25. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, et al. Prevention and treatment of cancer-related infections, Version 2.2016. J Natl Compr Cancer Netw. 2016;14(July):882–913.

    CAS  Google Scholar 

  26. Posaconazole [package insert]. Merck & Co., Inc. Whitehouse Station, NJ; 2014.

  27. Isavuconazole in preventing invasive fungal infections in adult patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome and neutropenia - full text view - ClinicalTrials.gov [Internet]. [cited 2019 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03019939?term=isavuconazole&draw=2&rank=2

  28. Fungal prophylaxis with isavuconazole for patients undergoing allogeneic hematopoietic stem cell transplant (HCT) - full text view - ClinicalTrials.gov [Internet]. [cited 2019 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03149055?term=isavuconazole&draw=2&rank=1

  29. •• Rausch CR, Dipippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin Infect Dis. 2018;67(10):1610–3 Retrospective review of 100 leukemic patients receiving isavuconazole for either IFI prophylaxis or treatment; 13 cases of breakthrough IFI reported.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. •• Fung M, Schwartz BS, Doernberg SB, Langelier C, Lo M, Graff L, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis. 2018;67(7):1142–3. Review of breakthrough invasive fungal infections of patients on isavuconazole prophylaxis at one center

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Marr KA. Mold infections after hematopoietic stem cell transplantation. In: Ljungman P, Snydman D, Boeckh M, editors. Transplant infections. 4th ed. Berlin: Springer International Publishing; 2016. p. 707–17.

    Google Scholar 

  32. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. van Burik J-AH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16.

    PubMed  Google Scholar 

  34. Gomes MZR, Jiang Y, Mulanovich VE, Lewis RE, Kontoyiannis DP. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother. 2014;58(5):2775–80.

    PubMed  PubMed Central  Google Scholar 

  35. Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens J, et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents. 2009;34(5):446–50.

    CAS  PubMed  Google Scholar 

  36. Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents. 2007;30(6):551–4.

    CAS  PubMed  Google Scholar 

  37. •• Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study. J Inf Secur. 2018;77(3):227–34 Randomized study comparing effectiveness and tolerability micafungin to posaconazole prophylaxis in the above high-risk groups which considers azole interactions with modern chemotherapy drugs.

    Google Scholar 

  38. • Almyroudis NG. Infections in Hematopoietic Stem Cell Transplant Recipients. In: Segal BH, editor. Management of infections in the immunocompromised host. Berlin: Springer International Publishing; 2018. p. 195–230. Book chapter inclusive of IFI prevention and treatment with references to drug-drug interactions among azoles and newer chemotherapy agents.

    Google Scholar 

  39. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43(5):577–84.

    CAS  PubMed  Google Scholar 

  40. Prasad A, Agarwal K, Deepak D, Atwal SS. Pulmonary aspergillosis: what CT can offer before it is too late! J Clin Diagn Res. 2016;10(4):TE01–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Sivak-Callcott JA, Livesley N, Nugent RA, Rasmussen SL, Saeed P, Rootman J. Localised invasive sino-orbital aspergillosis: characteristic features. Br J Ophthalmol. 2004;88(5):681–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39:3–22.

    CAS  PubMed  Google Scholar 

  43. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7–14.

    CAS  PubMed  Google Scholar 

  44. DePauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. Clin Infect Dis. 2008;46(12):1813–21.

    Google Scholar 

  45. • Gerritsen MG, Willemink MJ, Pompe E, Van Der Bruggen T, Van Rhenen A, Lammers JWJ, et al. Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography. PLoS One. 2017;12(2) e0172256.Use of low-dose CT to diagnose pulmonary infection in patients with febrile neutropenia.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70:270–7.

    PubMed  Google Scholar 

  47. Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Inf Secur. 2012;65(5):453–64.

    Google Scholar 

  48. • Sanguinetti M, Posteraro B, Beigelman-Aubry C, Lamoth F, Dunet V, Slavin M, et al. Diagnosis and treatment of invasive fungal infections: looking ahead. J Antimicrob Chemother. 2019;74:II27–37 Review of recent diagnostics and treatments for IFIs.

    CAS  Google Scholar 

  49. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54(SUPPL. 1):S55–60.

    PubMed  Google Scholar 

  50. Iwen PC, Thapa I, Bastola D. Review of methods for the identification of zygomycetes with an emphasis on advances in molecular diagnostics. Lab Med. 2011;42(5):260–6.

    Google Scholar 

  51. Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Ráčil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother. 2011;66(SUPPL. 1):i15.

    CAS  PubMed  Google Scholar 

  52. Kozel TR, Wickes B. Fungal diagnostics. Cold Spring Harb Perspect Med. 2014;4(4):a019299.

    PubMed  PubMed Central  Google Scholar 

  53. Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40(1):89–99.

    PubMed  Google Scholar 

  54. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Inf Secur. 2010;60(5):331–7.

    Google Scholar 

  55. Clancy CJ, Nguyen MH. Finding the missing 50% of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92.

    PubMed  Google Scholar 

  56. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–9.

    CAS  PubMed  Google Scholar 

  57. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190(3):641–9.

    CAS  PubMed  Google Scholar 

  58. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–60.

    PubMed  PubMed Central  Google Scholar 

  59. •• de Heer K, Gerritsen MG, Visser CE, Leeflang MM. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2019;2019:CD012399 Cochrane systematic review of the use of galactomannan from bronchoalveolar fluid in diagnosing invasive Aspergillosis.

  60. Leeflang MMG, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJPM, Hooft L, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2017:2015.

  61. • Haydour Q, Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, et al. Diagnosis of fungal infections. A systematic review and meta-analysis supporting American Thoracic Society Practice Guideline. Ann Am Thorac Soc. 2019;16(9):1179–88 Addresses use of BAL galactomannan and blood & BAL PCR in patients weith suspected invasive aspergillosis and other IFI.

    PubMed  Google Scholar 

  62. Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B. Fernández De Sevilla A, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59(12):1696–702.

    CAS  PubMed  Google Scholar 

  63. Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, Cavanna C, et al. Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol. 2012;50(3):1051–3.

    PubMed  PubMed Central  Google Scholar 

  64. Verweij PE, Mennink-Kersten MA. Issues with galactomannan testing. Med Mycol. 2006;44:S179–83.

    Google Scholar 

  65. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54(5):633–43.

    PubMed  Google Scholar 

  66. • Walsh TJ, McCarthy MW. The expanding use of matrix-assisted laser desorption/ionization-time of flight mass spectroscopy in the diagnosis of patients with mycotic diseases. Vol. 19, Expert review of molecular diagnostics. Taylor and Francis Ltd; 2019. p. 241–8. Reviews a diagnostic tool for invasive fungal infection.

  67. Powers-Fletcher MV, Hanson KE. Molecular diagnostic testing for Aspergillus. J Clin Microbiol. 2016;54(11):2655–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Aguado JM, Vazquez L, Fernandez-Ruiz M, Villaescusa T, Ruiz-Camps I, Barba P, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis. 2015;60(3):405–14.

    CAS  PubMed  Google Scholar 

  69. Lass-Florl C, Mutschlechner W, Aigner M, Grif K, Marth C, Girschikofsky M, et al. Utility of PCR in diagnosis of invasive fungal infections: Real-life data from a multicenter study. J Clin Microbiol. 2013;51(3):863–8.

    PubMed  PubMed Central  Google Scholar 

  70. Valero C, De La Cruz-Villar L, Zaragoza Ó, Buitrago MJ. New panfungal real-time PCR assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2016;54(12):2910–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49(suppl 1):7–10.

    CAS  PubMed  Google Scholar 

  73. • Aruanno M, Glampedakis E, Lamoth F. Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside. Antimicrob Agents Chemother. 2019;63(8):1–13 Revisits the use of echinocandins for invasive aspergillosis in the era of azole-resistance and more complex drug-drug interactions.

    Google Scholar 

  74. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis a randomized trial. Ann Intern Med. 2015;162(2):81–9.

    PubMed  Google Scholar 

  75. • Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;(24 Suppl 1):e1–38 European guideline for diagnosis and management of Aspergillus pertaining to patients with hematologic malignancy and HCT patients.

  76. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162–76.

    CAS  PubMed  Google Scholar 

  77. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.

    CAS  PubMed  Google Scholar 

  78. Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71(7):1786–99.

    CAS  PubMed  Google Scholar 

  79. Dekkers BGJ, Bakker M, van der Elst KCM, Sturkenboom MGG, Veringa A, Span LFR, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10(2):51–61.

    PubMed  PubMed Central  Google Scholar 

  80. Lempers VJC, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, et al. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharmacol. 2015;24:38–44.

    CAS  PubMed  Google Scholar 

  81. Sung L, Nathan PC, Alibhai SMH, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. American College of Physicians. 2007;147:400–11.

    PubMed  Google Scholar 

  82. Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014;20(11):O952–9.

    CAS  PubMed  Google Scholar 

  83. Hoenigl M, Raggam RB, Salzer HJF, Valentin T, Valentin A, Zollner-Schwetz I, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents. 2012;39(6):510–3.

    CAS  PubMed  Google Scholar 

  84. Pagano L, Caira M, Candoni A, Aversa F, Castagnola C, Caramatti C, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis. 2012;55(11):1515–21.

    CAS  PubMed  Google Scholar 

  85. • Tverdek FP, Heo ST, Aitken SL, Granwehr B, Kontoyiannis DP. Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses. Antimicrob Agents Chemother. 2017;61(8):e00188–17 Study reviewing posaconazole prophylaxis of invasive fungal infections in patients with hematologic malignancy at one center.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. • Tormo M, Pérez-Martínez A, Calabuig M, Hernández-Boluda JC, Amat P, Navarro D, et al. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: a real-world comparison. Mycoses. 2018;61(3):206–12 Retrospective review of primary prophylaxis of IFI with posaconazole vs itraconazole in hematologic malignancy patients.

    CAS  PubMed  Google Scholar 

  87. Cho SY, Lee DG, Choi SM, Choi JK, Lee HJ, Kim SH, et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. Mycoses. 2015;58(9):565–71.

    CAS  PubMed  Google Scholar 

  88. Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95(9):1435–55.

    PubMed  PubMed Central  Google Scholar 

  89. Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother. 2012;67(9):2268–73.

    CAS  PubMed  Google Scholar 

  90. Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year peXML: Please tag as article title.riod. Haematologica. 2012 Mar 1;97(3):459–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. • Hachem R, Assaf A, Numan Y, Shah P, Jiang Y, Chaftari AM, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Int J Antimicrob Agents. 2017;50(3):384–8 Retrospective study of IFI prophylaxis with voriconazole vs posaconazole in patients with hematologic malignancy at one center.

    CAS  PubMed  Google Scholar 

  92. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950–2.

    CAS  PubMed  Google Scholar 

  93. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5):451–6.

    CAS  PubMed  Google Scholar 

  94. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25(1):101–16.

    PubMed  Google Scholar 

  95. Nucci M, Anaissie E. How I Treat How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood. 2014;124(26):3858–69.

    CAS  PubMed  Google Scholar 

  96. Wingard JR. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol. 2005;17(2):89–92.

    PubMed  Google Scholar 

  97. • Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31:17–29 Retrospective cohort study characterizing IFIs with risk stratification based on hematologic malignancy.

    PubMed  Google Scholar 

  98. Verweij PE, Kerremans JJ, Voss A, JFGM M. Fungal contamination of tobacco and marijuana. J Am Med Assoc. 2000;284:2875.

    CAS  PubMed  Google Scholar 

  99. Khwaja S, Yacoub A, Cheema A, Rihana N, Russo R, Velez AP, et al. Marijuana smoking in patients with leukemia. Cancer Control. 2016 Jul;23(3):278–83.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

    Erica Stohs & Andrea Zimmer

Authors
  1. Erica Stohs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Zimmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erica Stohs.

Ethics declarations

Conflict of Interest

Andrea Zimmer reports grants from Astellas, Chimerix, and Ansum. Erica Stohs declares no conflict of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Current Management of Fungal Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stohs, E., Zimmer, A. An Approach to Suspected Invasive Fungal Infection in Patients with Hematologic Malignancy and HCT Recipients with Persistent Neutropenic Fever Despite Mold-Active Prophylaxis. Curr Fungal Infect Rep 14, 89–98 (2020). https://doi.org/10.1007/s12281-020-00375-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-020-00375-6

Keywords

Search

Navigation